Endo pain drug flunks a Ph2 test

A little more than two years after in-licensing a pain drug from Grunenthal, Endo Pharmaceuticals said today that the treatment failed a mid-stage, placebo-controlled study for lower back pain. Endo said it would complete its analysis of the data on axomadol and then decide how it would proceed with the program. Endo release